1 Zhou, F. et al. Identification of a high selective SMARCA2 degrader which effectively suppresses the SMARCA4-deficient tumors in vitro and in vivo. Cancer Research 83, 1137-1137 (2023).

2 Zhou, F. et al. SCR-8388, a potent and selective SOS1:: KRAS inhibitor, is effective in KRAS-addicted cancers. Cancer Research 83, 1724-1724 (2023).

3 Zhou, F. et al. Identification of SS008871, a novel Polθ inhibitor that effectively inhibits tumors with homologous recombination deficiency in vitro and in vivo. Cancer Research 83, 512-512 (2023).

4 Zhou, F. et al. Identification of SP-002, a highly selective USP1 inhibitor effectively inhibits HRD tumor growth and displays low hematotoxicity risk. Cancer Research 83, 6201-6201 (2023).

5 Zhou, F. et al. Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody. Cancer Research 83, 3474-3474 (2023).

6 Hu, Y. et al. Generation of a mutant SIRPa fusion protein with highly-improved affinity and favorable safety profile. Cancer Research 83, 6357-6357 (2023).

7 Goh, C. W. et al. Abstract P5-02-53: P95HER2 Expression in HER2-Positive Breast Cancer. Cancer Research 83, P5-02-53-P05-02-53 (2023).

8 Zhu, D. et al. Long-chain Non-coding RNA MIR4435-2HG Expression Correlates With Size of Intestinal Polyps in Children and With Metastasis of Colon Cancer. Anticancer research 42, 4707-4714, doi:10.21873/anticanres.15975 (2022).

9 Zhou, F. et al. Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers. Cancer Research 82, 5642-5642 (2022).

10 Zhou, F. et al. SCR-6277, a potent and high selective arginine methyltransferase 5 (PRMT5) inhibitor with high tumor/plasma distribution ratio demonstrated robust anti-tumor activities and decreased hematological toxicities. Cancer Research 82, 2157-2157 (2022).

11 Zhou, F. et al. Discovery of SCR-7952, a novel, potent and high selective MAT2A inhibitor shows robust anti-tumor activities and better safety profile. Cancer Research 82, 5434-5434 (2022).

12 Zhou, F. et al.     (BMJ Publishing Group Ltd, 2022).

13 Zhao, X. et al. Discovery and development of SLD2435, a novel humanized IgG1 bispecific antibody simultaneously targeting human TIGIT and PVRIG for cancer immunotherapy. Cancer Research 82, 5203-5203 (2022).

14 Yang, C. et al. A multispecific T cell engager binding to both membrane proximal and membrane distal epitopes of MSLN with low affinity CD3 for the treatment of AML and solid tumors. Cancer Research 82, 6343-6343 (2022).

15 Yan, Y. et al. Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs. Journal of Immunological Sciences 6, 18-24 (2022).

16 Xue, L. et al. An antiangiogenic agent associated with multi-targets exhibits synergistic antitumor effects in combination with immunotherapeutics. J. Oncol. Res. Ther 7, 10.29011 (2022).

17 Hu, Y. et al. in ARTHRITIS & RHEUMATOLOGY.  1176-1177 (WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA).

18 Gu, P. et al. Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors. Frontiers in Oncology 12, 885186 (2022).

19 Gu, P. et al. Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer. Cancer Research 82, 5441-5441 (2022).

20 , L. G., X Qin, L Xue, J Yang, Y Zhang, S Zhu, G Ye, R Tang*, WQ Yang*. A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents. Frontiers in Pharmacology (2022).

21 Zhou, F. et al. SCR6106, an oral and brain penetrant SERD demonstrated anti-tumor activities in vitro and in vivo. Cancer Research 81, 1070-1070 (2021).

22 Zhao, X. et al. Generation and validation of a novel humanized TNFR2 mouse model for the evaluation of therapeutic TNFR2 antibody. Cancer Research 81, 1814-1814 (2021).

23 Zhao, X. et al. Dissecting the mechanism of action targeting TNFR2 with a lignd blocking anti-TNFR2 antibody that elicits potent anti-tumor activity. Cancer Research 81, 1029-1029 (2021).

24 Xue, L. et al. Combination of an anti-angiogenic antibody with PD1/PDL1 blockade agents produces synergistic anti-tumor efficacy in preclinical models. Cancer Research 81, 2651-2651 (2021).

25 Xue, L. et al. Abstract P001: The anti-angiogenic antibody BD0801 demonstrates better anti-tumor activity than bevacizumab and synergize with chemotherapies in multiple tumor models. Molecular Cancer Therapeutics 20, P001-P001 (2021).

26 Xue, L. et al. in MOLECULAR CANCER THERAPEUTICS.   (AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA …).

27 Xue, L. et al. Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment. BMC cancer 21, 1-14 (2021).

28 Sun, J. et al. Anti-inflammatory and Anti-thrombotic Efficacy of Targeted Ultrasound Microbubbles on LPS-induced HUVEC Cells. Anticancer research 41, 4761-4769, doi:10.21873/anticanres.15291 (2021).

29 Liu, Y. et al. Establishment and validation of humanized murine modeling platforms to facilitate immuno-oncology research. Cancer Research 81, 2981-2981 (2021).

30 Li, Y. et al. APELA/ELA32 Reduces Iodixanol-induced Apoptosis, Inflammatory Response and Mitochondrial and DNA Damage in Renal Tubular Epithelial Cells. Anticancer research 40, 635-643, doi:10.21873/anticanres.13993 (2020).

31 Zang, W. et al. Traditional Chinese Medicine (TCM) Astragalus Membranaceus and Curcuma Wenyujin Promote Vascular Normalization in Tumor-derived Endothelial Cells of Human Hepatocellular Carcinoma. Anticancer research 39, 2739-2747, doi:10.21873/anticanres.13400 (2019).

32 Xu, X. et al. Establishment and characterization of 3D cancer organoids as clinically relevant ex vivo drug screening tools for cancer translational research and drug discovery. Cancer Research 79, 1925-1925 (2019).

33 Xu, X. et al. β-Catenin Expression Correlates With Prognosis in Hepatocellular Carcinoma Patients Treated With Transcatheter Arterial Chemoembolization. Anticancer research 39, 1129-1134, doi:10.21873/anticanres.13221 (2019).

34 Xia, N. et al. Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of (125)I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma. Anticancer research 39, 5919-5925, doi:10.21873/anticanres.13796 (2019).

35 Lu, Y. et al. Double-negative T Cells Inhibit Proliferation and Invasion of Human Pancreatic Cancer Cells in Co-culture. Anticancer research 39, 5911-5918, doi:10.21873/anticanres.13795 (2019).

36 Liu, J. B. et al. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus. Anticancer research 39, 1689-1698, doi:10.21873/anticanres.13274 (2019).

37 Liu, J. B. et al. Aurora-A/NF-ĸB Signaling Is Associated With Radio-resistance in Human Lung Adenocarcinoma. Anticancer research 39, 5991-5998, doi:10.21873/anticanres.13804 (2019).

38 Liu, C. et al. Knockdown of Histone Methyltransferase WHSC1 Induces Apoptosis and Inhibits Cell Proliferation and Tumorigenesis in Salivary Adenoid Cystic Carcinoma. Anticancer research 39, 2729-2737, doi:10.21873/anticanres.13399 (2019).

39 Lin, A. E. et al. Experimental modeling of acute-and chronic-GvHD by xenotransplanting human donor PBMCs or cord blood CD34+ cells (HSC) into NSG mice. Cancer Research 79, 2342-2342 (2019).

40 Hoffman, R. M. et al. Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. Methods Mol Biol 1866, 211-229, doi:10.1007/978-1-4939-8796-2_16 (2019).

41 He, C. et al. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma. Anticancer research 39, 1711-1718, doi:10.21873/anticanres.13277 (2019).

42 Ge, H. et al. AMMECR1 Inhibits Apoptosis and Promotes Cell-cycle Progression and Proliferation of the A549 Human Lung Cancer Cell Line. Anticancer research 39, 4637-4642, doi:10.21873/anticanres.13644 (2019).

43 Zhang, L. et al. Abstract B28: Validation and characterization of MiXeno humanized mouse models for immuno-oncology. Cancer Immunology Research 6, B28-B28 (2018).

44 Zhang, L. et al. in MOLECULAR CANCER THERAPEUTICS.   (AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA …).

45 Zhang, L. et al. Abstract B078: MiXenoTM: a fast and efficient humanized tumor model system for in vivo efficacy evaluation of novel immunotherapeutics. Molecular Cancer Therapeutics 17, B078-B078 (2018).

46 Zhang, L. et al. Establishment and application of a panel of PBMC-humanized mouse tumor models in immune-oncology and targeted cancer immunotherapy. Cancer Research 78, 5677-5677 (2018).

47 Yuan, H. et al. Ultrasound Microbubble Delivery Targeting Intraplaque Neovascularization Inhibits Atherosclerotic Plaque in an APOE-deficient Mouse Model. In Vivo 32, 1025-1032, doi:10.21873/invivo.11342 (2018).

48 Yang, W. et al. Abstract B008: PD-1/PDL-1 blockade remarkably regulates abundance of gut commensal microbiota in a murine syngeneic tumor model. Molecular Cancer Therapeutics 17, B008-B008 (2018).

49 Yang, G. et al. Traditional Chinese Medicine Curcumin Sensitizes Human Colon Cancer to Radiation by Altering the Expression of DNA Repair-related Genes. Anticancer research 38, 131-136, doi:10.21873/anticanres.12200 (2018).

50 Wang, W. et al. Ethanolic Extract of Traditional Chinese Medicine (TCM) Gamboge Inhibits Colon Cancer via the Wnt/Beta-Catenin Signaling Pathway in an Orthotopic Mouse Model. Anticancer research 38, 1917-1925, doi:10.21873/anticanres.12429 (2018).

51 Wang, Q. et al. Moesin Up-regulation Is Associated with Enhanced Tumor Progression Imaged Non-invasively in an Orthotopic Mouse Model of Human Glioblastoma. Anticancer research 38, 3267-3272, doi:10.21873/anticanres.12591 (2018).

52 Lin, A. E. et al. Experimental Modeling of Acute-and Chronic-GvHD By Xenotransplanting Human Donor PBMCs or Cord Blood CD34+ Cells (HSC) into NSG Mice. Blood 132, 5684 (2018).

53 Jin, Y. et al. in MOLECULAR CANCER THERAPEUTICS.   (AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA …).

54 Jin, Y. et al. Abstract B014: MuScreen allows profiling of antitumor efficacy and biomarker readouts of drug candidates using well-characterized syngeneic models. Molecular Cancer Therapeutics 17, B014-B014 (2018).

55 Fang, T. et al. Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer. Anticancer research 38, 179-186, doi:10.21873/anticanres.12206 (2018).

56 Chen, F. et al. Commensal microbiota is involved in anti-PD-1 mAb-mediated antitumor activity in a preclinical tumor model. Cancer Research 78, 1264-1264 (2018).

57 Cai, J. et al. Development of murine tumor homograft panels and their genetic fingerprints for their identification to ensure the quality controlled I/O studies using these models. Cancer Research 78, 5116-5116 (2018).

58 Zheng, B. et al. CC-90002 (anti-CD47 antibody) in vivo anti-tumor activity is associated with an increase in M1-polarized macrophages. Cancer Research 77, 2009-2009 (2017).

59 Zhang, W. et al. Chemoprevention by Quercetin of Oral Squamous Cell Carcinoma by Suppression of the NF-κB Signaling Pathway in DMBA-treated Hamsters. Anticancer research 37, 4041-4049, doi:10.21873/anticanres.11789 (2017).

60 Zhang, S. et al. Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma. Anticancer research 37, 465-473, doi:10.21873/anticanres.11338 (2017).

61 Zhang, L. et al. in JOURNAL FOR IMMUNOTHERAPY OF CANCER.   (BMC CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND).

62 Xu, X. et al. Enhancement of Wound Healing by the Traditional Chinese Medicine Herbal Mixture Sophora flavescens in a Rat Model of Perianal Ulceration. In Vivo 31, 543-549, doi:10.21873/invivo.11092 (2017).

63 Wang, Q. et al. Moesin Expression Is Associated with Glioblastoma Cell Proliferation and Invasion. Anticancer research 37, 2211-2218, doi:10.21873/anticanres.11556 (2017).

64 Narla, R. K. et al. The humanized anti-CD47 monclonal antibody, CC-90002, has antitumor activity in vitro and in vivo. Cancer Research 77, 4694-4694 (2017).

65 Dai, X. et al. Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model. Anticancer research 37, 979-986, doi:10.21873/anticanres.11407 (2017).

66 Zhang, Y. et al. Real-Time GFP Intravital Imaging of the Differences in Cellular and Angiogenic Behavior of Subcutaneous and Orthotopic Nude-Mouse Models of Human PC-3 Prostate Cancer. J Cell Biochem 117, 2546-2551, doi:10.1002/jcb.25547 (2016).

67 Yang, H. et al. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma. Anticancer research 36, 2675-2682 (2016).

68 Xu, X. et al. Therapeutic Efficacy of the Traditional Chinese Medicine Baishaoqiwu on TNBS-induced Colitis is Associated with Down-regulation of the TLR4/MyD88/NF-κB Signaling Pathway. In Vivo 30, 181-186 (2016).

69 Wang, M. et al. Bone Marrow Mesenchymal Stem Cells Reverse Liver Damage in a Carbon Tetrachloride-induced Mouse Model of Chronic Liver Injury. In Vivo 30, 187-193 (2016).

70 Sun, J. et al. Decreased Expression of Tumor-suppressor Gene LKB1 Correlates with Poor Prognosis in Human Gastric Cancer. Anticancer research 36, 869-875 (2016).

71 Yin, G. et al. Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein. Anticancer research 35, 3193-3207 (2015).

72 Mortensen, D. S. et al. CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization. Molecular cancer therapeutics 14, 1295-1305 (2015).

73 Yang, W., Jiu, J., Narla, R. K. & Raymon, H. K. Evaluation of the TOR kinase inhibitor CC214-2 in a mouse model of hormone-refractory prostate cancer. Cancer Research 74, 4517-4517 (2014).

74 Lee, S. E. et al. Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use. Pharm Dev Technol 19, 438-453, doi:10.3109/10837450.2013.789911 (2014).

75 Wu, J. et al. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model. Anticancer research 33, 419-424 (2013).

76 Shi, Y. et al. VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model. Anticancer research 33, 409-417 (2013).

77 Wang, M. et al. Efficacy of the Chinese traditional medicinal herb Celastrus orbiculatus Thunb on human hepatocellular carcinoma in an orthothopic fluorescent nude mouse model. Anticancer research 32, 1213-1220 (2012).

78 Ma, H. et al. High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate. J Surg Res 171, 684-690, doi:10.1016/j.jss.2010.05.066 (2011).

79 Sakuma, S. et al. Detection of early colorectal cancer imaged with peanut agglutinin-immobilized fluorescent nanospheres having surface poly(N-vinylacetamide) chains. Eur J Pharm Biopharm 74, 451-460, doi:10.1016/j.ejpb.2010.01.001 (2010).

80 Drapeau, C. et al. Mobilization of bone marrow stem cells with StemEnhance improves muscle regeneration in cardiotoxin-induced muscle injury. Cell Cycle 9, 1819-1823, doi:10.4161/cc.9.9.11540 (2010).

81 Sakuma, S. et al. In vitro/in vivo biorecognition of lectin-immobilized fluorescent nanospheres for human colorectal cancer cells. J Control Release 134, 2-10, doi:10.1016/j.jconrel.2008.10.017 (2009).

82 Mutka, S. C. et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer research 69, 510-517 (2009).

83 Matsuo, Y. et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 125, 1027-1037, doi:10.1002/ijc.24383 (2009).

84 Ma, H. et al. Efficacy of dietary antioxidants combined with a chemotherapeutic agent on human colon cancer progression in a fluorescent orthotopic mouse model. Anticancer research 29, 2421-2426 (2009).

85 Drapeau, C. et al. The stem cell mobilizer StemEnhance does not promote tumor growth in an orthotopic model of human breast cancer. Anticancer research 29, 443-447 (2009).

86 Yang, W. et al. Anti-tumor activity of novel nuclear export inhibitors (NEIs) in multiple murine leukemia models. Cancer Research 68, 5688-5688 (2008).

87 Mutka, S. et al. Mechanistic analyses of the therapeutic activity of nuclear export inhibitors (NEIs) in cancer. Cancer Research 68, 1591-1591 (2008).

88 Duan, J. X. et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 51, 2412-2420, doi:10.1021/jm701028q (2008).

89 Yang, W. et al. Anti-tumor activity of novel nuclear export inhibitors (NEIs) in multiple xenograft models. Cancer Research 67, 5597-5597 (2007).

90 Mutka, S. et al. Nuclear export inhibitors (NEIs) as novel cancer therapeutics. Cancer Research 67, 5609-5609 (2007).

91 Ammons, W. S., Wang, J. W., Yang, Z., Tidmarsh, G. F. & Hoffman, R. M. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia 9, 625-633, doi:10.1593/neo.07343 (2007).

92 Zhao, M. et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 66, 7647-7652, doi:10.1158/0008-5472.Can-06-0716 (2006).

93 Berezovska, O. P. et al. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5, 1886-1901, doi:10.4161/cc.5.16.3222 (2006).

94 Sun, X., Tan, Y., Yang, Z., Li, S. & Hoffman, R. M. A rapid HPLC method for the measurement of ultra-low plasma methionine concentrations applicable to methionine depletion therapy. Anticancer research 25, 59-62 (2005).

95 Lun, X. et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer research 65, 9982-9990 (2005).

96 Yang, Z. et al. Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin Cancer Res 10, 2131-2138, doi:10.1158/1078-0432.ccr-03-0068 (2004).

97 Yang, Z. et al. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 64, 6673-6678, doi:10.1158/0008-5472.Can-04-1822 (2004).

98 Yang, Z. et al. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate. Cancer Res 64, 5775-5778, doi:10.1158/0008-5472.Can-04-1406 (2004).

99 Yang, W. Q. et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clinical cancer research 10, 8561-8576 (2004).

100 Yang, W. et al. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene therapy 11, 1579-1589 (2004).

101 Li, S. et al. Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation. Anal Biochem 330, 264-271, doi:10.1016/j.ab.2004.03.034 (2004).

102 Yang, W. Q. et al. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer research 63, 3162-3172 (2003).

103 Sun, X. et al. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation. Cancer Res 63, 8377-8383 (2003).

104 Li, S. et al. A simultaneous colorimetric assay of free and protein-coupled polyethylene glycol. Anal Biochem 313, 335-337, doi:10.1016/s0003-2697(02)00593-6 (2003).

105 Wilcox, M. E. et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. Journal of the National Cancer Institute 93, 903-912 (2001).

106 Song, Y.-h. et al. Immunohistochemical observation of macrophage colony stimulating factor and its receptor in breast cancer and hepatoma tissues. Chinese Journal of Cancer Research 13, 1-4 (2001).

107 Yang, W. et al. Co-expression of macrophage colony-stimulating factor with its receptor in human hepatoma cells and its potential roles. Chinese Journal of Cancer Research 11, 79-84 (1999).

108 Wu, K.-F. et al. Cellular macrophage colony-stimulating factor and its role. Haematologica 84, 951-952 (1999).

109 Wen-Qing, Y., Nai-Guo, S., Shu-Shen, Y. & Hua-Qi, L. Serum lipid concentrations correlate with the progression of chronic renal failure. Clinical Laboratory Science 12, 104 (1999).

110 Yang, W., Wu, K. & Song, N. The role of macrophage colony-stimulating factor in development of atherosclerosis and chronic renal failure. Foreign Med Sci J Clin biochem Lab 19, 220-220 (1998).

111 Song, N. et al. An alternative method for evaluating lipoprotein (a) excess in plasma. Clinical Laboratory Science: Journal of the American Society for Medical Technology 10, 325-328 (1997).

112 Guo, L. et al. A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents. Frontiers in Pharmacology, 3323.

113 Macrophage colony stimulating factor and its receptor maybe involved in human hepatoma growth regulation.